RxSight (RXST) Q3 2024: LDD Installed Base Jumps 51% as Premium IOL Adoption Deepens

2024-11-09 | By EarningsIQ Research

RxSight’s installed base of Light Delivery Devices (LDDs) surged, reflecting accelerating adoption of its light-adjustable intraocular lens (LAL) system in premium cataract surgery. Robust LDD placements and a rising mix of high-margin LAL sales highlight RxSight’s ability to capture share and drive margin expansion, despite seasonal and weather-related headwinds. Upward guidance revision and global expansion signals set the stage for further penetration in North America and key international markets.

Summary

• Installed Base Expansion: LDD placements outpaced typical seasonality, fueling broader system adoption.
• Margin Leverage: Higher LAL mix and manufacturing scale drove significant gross margin improvement.
• Global Growth Catalyst: Regulatory progress in Asia and Europe positions RxSight for international premium IOL market entry.

Business Overview

RxSight develops and sells the first and only FDA-approved light adjustable lens (LAL) system for premium cataract surgery. The business model combines sales of LALs, a premium intraocular lens that can be adjusted postoperatively with ultraviolet light, and Light Delivery Devices (LDDs), the capital equipment required for the adjustment process. Revenue is generated through both recurring LAL consumable sales and LDD capital placements, with North America as the primary market and early-stage international expansion underway.

Performance Analysis

RxSight’s third quarter demonstrated strong execution in driving LDD placements and deepening LAL penetration, despite typical summer seasonality and hurricane-related disruptions in key southern markets. LDD unit sales matched record Q2 levels, with the installed base growing 51% year-over-year, underscoring sustained demand from both new and existing practices. LAL sales, while seasonally softer, still grew 79% year-over-year and accounted for 69% of total revenue, up from 61% a year ago, reflecting a strategic shift toward higher-margin recurring revenue.

Gross margin expanded to 71.4% from 61.9% last year, driven by favorable product mix, manufacturing efficiencies, and stable pricing for both LAL and LDD. Operating expenses increased at a slower pace than revenue, resulting in a sharply reduced net loss and a small non-GAAP profit. Cash burn was muted, with a strong balance sheet supporting continued investment in commercial expansion and R&D.

• Installed Base Momentum: LDD placements held steady sequentially, defying typical Q3 capital equipment softness and signaling robust practice-level ROI.
• Utilization Dynamics: Average monthly LALs per LDD dipped sequentially due to seasonality, but annual utilization trends remain upward as newer practices ramp faster.
• Pricing Stability: Both LAL and LDD average selling prices held firm, with no customer pushback, supporting margin durability.

Seasonal factors and hurricane impacts were acknowledged but seen as temporary, with management confident that Q4 would see a rebound as practices recover and patient volumes normalize.

Executive Commentary

Strategic Positioning

1. Installed Base Expansion and Penetration

RxSight’s LDD installed base growth is a leading indicator of long-term recurring revenue. Practices are adding second and third LDDs as utilization ramps, with ROI typically realized within six months. This expansion is driven by both new customer wins and deepening penetration at existing accounts.

2. Product Innovation and Mix Shift

LAL Plus, the next-generation lens, is now fully rolled out in the U.S. and approved in Canada, offering superior near vision and broadening the addressable market. The upcoming launch of low-diopter LAL Plus powers will extend RxSight’s reach to patients with a wider range of refractive needs, further differentiating its platform from fixed-power IOL competitors.

3. Commercial Model and Channel Leverage

RxSight’s sales and clinical field teams (now 165 strong) are focused on both onboarding new accounts and driving deeper utilization within existing practices. The company’s optometrist engagement program leverages the critical gatekeeper role of optometrists in patient referral and postoperative care, aiming to accelerate adoption and build grassroots advocacy.

4. International Expansion Readiness

Regulatory filings in Asia and Europe are underway, with management expecting first approvals and commercial pilots in the coming months. The company will tailor its go-to-market strategy by region, using distributors in some markets (as in Canada) and direct sales in others, leveraging U.S. playbook learnings while adapting to local practice structures.

5. Margin Structure and Cost Discipline

Margin gains are structurally supported by the shift toward LAL consumables and ongoing manufacturing scale. Management expects current gross margin levels to be sustainable, with further upside as volume increases and cost per unit declines lag six to nine months behind production scale.

Key Considerations

This quarter’s results reflect RxSight’s ability to drive both top-line growth and operating leverage, while setting the stage for global expansion and deeper market penetration. Investors should weigh the following:

• Capital Placement Resilience: LDD demand remains robust, with practices motivated by rapid payback and high patient satisfaction, even amid broader capital equipment caution in healthcare.
• Seasonality and External Disruptions: Q3 softness in LAL sales was attributed to doctor/patient vacations and hurricane-related closures, but management expects normalization in Q4.
• Practice Utilization Ramp: Newer practices reach mature utilization levels faster, aided by field team support and ongoing product innovation.
• Optometrist Engagement: The expanding optometrist initiative is a strategic lever to increase patient referrals and drive LAL adoption at scale.
• International Market Entry: OUS markets represent 80% of the premium IOL opportunity, with first regulatory milestones expected in the next several months.

Risks

RxSight faces several execution risks as it scales: Seasonality and weather events can disrupt procedure volumes, as seen in Q3. International expansion will require careful localization of the commercial model and regulatory navigation, with potential delays or slower-than-expected uptake. Competitive responses from established IOL manufacturers, reimbursement pressures, and the need to maintain high clinical outcomes across a growing installed base are ongoing challenges. Management’s ability to sustain pricing and margin discipline as volumes scale is critical for long-term profitability.

Forward Outlook

For Q4 2024, RxSight guided to:

• Revenue of approximately $40 million
• Gross margin similar to Q3 (70% to 71%)
• Operating expense at the low end of $37 to $38 million

For full-year 2024, management raised guidance:

• Revenue of approximately $140 million (top end of prior range)
• Gross margin of 70% to 71% (up from 68% to 70%)
• Operating expenses at the low end of $135 to $136 million

Management highlighted several factors that underpin this outlook:

• Continued high demand for LDD placements and recurring LAL sales
• Recovery from Q3 disruptions and a historically strong Q4 for both capital and procedure volumes

Takeaways

RxSight’s Q3 results reinforce its position as an innovation leader in premium cataract surgery, with strong installed base growth, margin expansion, and a clear path to global market entry.

• Structural Margin Gains: The shift to higher LAL mix and manufacturing scale is driving sustainable gross margin improvement, supporting a path to profitability.
• Installed Base Drives Recurring Revenue: LDD placements are a leading indicator of future LAL sales, with field teams accelerating both new account wins and utilization ramp.
• Global and Channel Expansion: Regulatory progress in key OUS markets and optometrist engagement in North America are strategic levers for the next phase of growth.

Conclusion

RxSight’s Q3 performance demonstrates robust execution in expanding its premium IOL platform, leveraging both product innovation and commercial discipline. With upgraded guidance and global expansion on the horizon, RxSight is well positioned to extend its leadership in the premium cataract surgery market.

Industry Read-Through

RxSight’s accelerating LDD placements and margin expansion signal a broader shift toward premium, patient-pay solutions in ophthalmology. The company’s success with a postoperatively adjustable IOL platform highlights increasing demand for customizable outcomes and practice-level ROI, putting pressure on legacy IOL providers to innovate. Capital equipment ROI and recurring consumables models are gaining traction, with optometrist engagement emerging as a key referral and adoption lever. As reimbursement pressures persist, practices are seeking scalable, high-margin offerings—an industry trend likely to benefit other premium device innovators and challenge commoditized players.

RXST Health Care Medical Devices Premium IOL Consumables Installed Base International Expansion Ophthalmology